These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11177319)

  • 1. Breaking the camel's back: multicenter clinical trials and local institutional review boards.
    Burman WJ; Reves RR; Cohn DL; Schooley RT
    Ann Intern Med; 2001 Jan; 134(2):152-7. PubMed ID: 11177319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Institutional review boards: a crisis in confidence.
    Levine RJ
    Ann Intern Med; 2001 Jan; 134(2):161-3. PubMed ID: 11177321
    [No Abstract]   [Full Text] [Related]  

  • 4. Changing the paradigm: new directions in federal oversight of human research.
    Koski G
    J Pediatr Gastroenterol Nutr; 2003; 37 Suppl 1():S2-6. PubMed ID: 14685070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance.
    Vardeny O; Hernandez AF; Cohen LW; Franklin A; Baqai M; Palmer S; Bierer BE; Cobb N
    Clin Trials; 2019 Jun; 16(3):290-296. PubMed ID: 30866676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Problematic variation in local institutional review of a multicenter genetic epidemiology study.
    McWilliams R; Hoover-Fong J; Hamosh A; Beck S; Beaty T; Cutting G
    JAMA; 2003 Jul; 290(3):360-6. PubMed ID: 12865377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current issues surrounding women and minorities in drug trials.
    Wermeling DP; Selwitz AS
    Ann Pharmacother; 1993; 27(7-8):904-11. PubMed ID: 8364277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in institutional review board responses to a standard protocol for a multicenter clinical trial.
    Stair TO; Reed CR; Radeos MS; Koski G; Camargo CA;
    Acad Emerg Med; 2001 Jun; 8(6):636-41. PubMed ID: 11388939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability among institutional review boards' decisions within the context of a multicenter trial.
    Silverman H; Hull SC; Sugarman J
    Crit Care Med; 2001 Feb; 29(2):235-41. PubMed ID: 11246299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration.
    Bramstedt KA; Kassimatis K
    Clin Invest Med; 2004 Dec; 27(6):316-23. PubMed ID: 15675112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IRBs search for answers and support during a time of institutional change.
    Phillips DF
    JAMA; 2000 Feb; 283(6):729-30. PubMed ID: 10683041
    [No Abstract]   [Full Text] [Related]  

  • 12. IRBs and monitoring the safety of clinical trials.
    Maloney DM
    Hum Res Rep; 2003 Jan; 18(1):3. PubMed ID: 12755095
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of central institutional review boards for multicenter clinical trials in the United States: a review of the literature.
    Check DK; Weinfurt KP; Dombeck CB; Kramer JM; Flynn KE
    Clin Trials; 2013 Aug; 10(4):560-7. PubMed ID: 23666951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duke's hazards. Did medical experiments put patients needlessly at risk?
    Kaplan S; Brownlee S
    US News World Rep; 1999 May; 126(20):66-8, 70. PubMed ID: 10387890
    [No Abstract]   [Full Text] [Related]  

  • 15. Shutdown of research at Duke sends a message.
    Marshall E
    Science; 1999 May; 284(5418):1246. PubMed ID: 10383299
    [No Abstract]   [Full Text] [Related]  

  • 16. Current issues in clinical research and the development of new pharmaceuticals.
    Goldhammer A
    Account Res; 2001; 8(4):283-91. PubMed ID: 12481798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oversight mechanisms for clinical research.
    Snyderman R; Holmes EW
    Science; 2000 Jan; 287(5453):595-7. PubMed ID: 10691540
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical trial monitoring: hit or miss?
    Cohen J
    Science; 1994 Jun; 264(5165):1534-7. PubMed ID: 8202707
    [No Abstract]   [Full Text] [Related]  

  • 19. Federal commissions and local IRBs.
    Yesley MS
    Hastings Cent Rep; 1983 Oct; 13(5):11-2. PubMed ID: 6643032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protecting research subjects--the crisis at Johns Hopkins.
    Steinbrook R
    N Engl J Med; 2002 Feb; 346(9):716-20. PubMed ID: 11870258
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.